Skip to main content
. Author manuscript; available in PMC: 2018 Dec 1.
Published in final edited form as: J Surg Oncol. 2017 Jun 19;116(7):898–906. doi: 10.1002/jso.24733

Figure 4.

Figure 4

(A) Representative images of tittered cetuximab-IRDye800CW concentrations in tumors containing cells incubated at either 24 or 72-hours. (B) Tumor-to-background ratios of tumors following 1, 24, and 72-hour incubation times are shown for each concentration tested. (C) Representative images of tittered cetuximab-IRDye800CW (8.6×10−2 μM) incubated cell numbers in tumors containing cells incubated at either 24 or 72-hours. (D) Tumor-to-background ratios of tumors following 1, 24, and 72-hour incubation times are shown for each cell number tested.